Get the Stockscreener App
2.81
3.44%
-0.10
After Hours:
2.80
-0.01
-0.36%
Longeveron Inc stock is traded at $2.81, with a volume of 50,134.
It is down -3.44% in the last 24 hours and up +313.24% over the past month.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.
See More
Previous Close:
$2.91
Open:
$2.89
24h Volume:
50,134
Relative Volume:
0.14
Market Cap:
$8.96M
Revenue:
$1.22M
Net Income/Loss:
$-22.43M
P/E Ratio:
-2.43
EPS:
-1.1564
Net Cash Flow:
$-18.78M
1W Performance:
+12.85%
1M Performance:
+313.24%
6M Performance:
+188.77%
1Y Performance:
+254.08%
1-Day Range:
$2.76
$2.95
1-Week Range:
$2.32
$2.97
52-Week Range:
$0.475
$7.60
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
2.81 | 8.96M | 1.22M | -22.43M | -18.78M | -1.1564 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Longeveron ELPIS II Miss, Strategic Review and Refocus - tipranks.com
Longeveron reports ELPIS II misses primary endpoint; to analyze data, explore strategic options - TradingView
Longeveron starts strategic review after laromestrocel failure to improve heart function in HLHS infants - AllSci
Longeveron Shares Plunge 60% After Pediatric Stem Cell Therapy Misses Primary Goal - finance.biggo.com
Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value? - Yahoo Finance
Longeveron Stock Price Forecast. Should You Buy LGVN? - StockInvest.us
Longeveron shares plunge 59% as HLHS heart therapy misses endpoint - The Pharma Letter
Longeveron slides 59% after-hours from stem cell therapy study failure - Mugglehead Investment Magazine
Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why - webull.com
Longeveron to carry on? Shortfall in HLSH phase IIb - BioWorld News
Longeveron stock plunges 50% after trial misses primary endpoint By Investing.com - Investing.com Nigeria
Longeveron stock plunges 50% after trial misses primary endpoint - Investing.com
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) - BioSpace
Longeveron to resume trading at 5:55 pm ET - TipRanks
Longeveron exploring all options for maximizing shareholder value - TipRanks
Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition - Yahoo Finance
Longeveron Shares Halted After Heart Therapy Trial Misses Primary Endpoint - marketscreener.com
Longeveron Announces ELPIS II Results, Reviews Strategic Alternatives to Maximize Shareholder Value - quiverquant.com
Logos Global Management LP Adds Longeveron Inc (LGVN) Shares -- Stock Looks 118% Overvalued on GF Value - gurufocus.com
Longeveron Regains Nasdaq Compliance With Minimum Bid Price - TipRanks
192,308 Longeveron (NASDAQ: LGVN) shares sit with one passive fund - Stock Titan
LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Longeveron Inc. of Class Action Lawsuit and Upcoming DeadlineLGVN - TMX Newsfile
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
A biotech presentation is set for New York on Sept. 14 - Stock Titan
Longeveron | 4: Statement of changes in beneficial ownership of securities - Moomoo
Longeveron (LGVN) Gains 2.68% as Shares Hold Above Key Support at $6.55Breakout Confirmation - vinanet.vn
Longeveron To Carry Out 1-for-10 Reverse Stock Split On August 27th, 2026 - Moomoo
Longeveron Announces 1-for-10 Reverse Stock Split to Regain Nasdaq Compliance - Intellectia AI
Longeveron Announces 1-for-10 Reverse Stock Split - The Manila Times
Longeveron Inc. Earnings Call: Trials, Cash and Risk - TipRanks
Longeveron (NASDAQ: LGVN) insider logs new stock trades - Stock Titan
Longeveron (LGVN) grants director 36,000 stock units - Stock Titan
Longeveron (NASDAQ: LGVN) insider reports new stock dealings - Stock Titan
Longeveron (LGVN) insider logs new stock transactions in company shares - stocktitan.net
Longeveron (LGVN) Q2 2026 Earnings Call Transcript - AOL.ca
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer - manilatimes.net
Longeveron (LGVN) Earnings Reading: Profit Per Share Falls Below Its Benchmark at the Close; After Results: The Stock Gains 4.46% in the Current UpdateProfitability Analysis - vinanet.vn
Longeveron appoints Nirav Jhaveri as chief financial officer - Investing.com Nigeria
Longeveron Appoints Nirav Jhaveri as CFO Ahead of September Trial Data - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Longeveron CFO Marie Washburn to switch roles, Nirav Jhaveri to succeed - TipRanks
Longeveron Appoints New Chief Financial Officer Jhaveri - TipRanks
Longeveron Appoints Nirav Jhaveri As CFO - marketscreener.com
Longeveron appoints Nirav Jhaveri as chief financial officer By Investing.com - Investing.com India
Longeveron Inc. Appoints Nirav Jhaveri as Chief Financial Officer - Quiver Quantitative
Marie Washburn Net Worth (2026) - GuruFocus
Longeveron reports Q2 EPS (19c) vs. (33c) last year - TipRanks
$Longeveron (LGVN.US)$ - Moomoo
Longeveron Inc. (LGVN) investors disclose 9% beneficial stake through warrant holdings - Stock Titan
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):